NCT00318500View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

December 31, 2006

Conditions
DysmenorrheaDyspareuniaEndometriosisPelvic Pain
Interventions
DRUG

ERB-041

Trial Locations (70)

200

Sydney

1724

Roodepoort

2031

Randwick

3000

Herestraat

3121

Richmond

4320

Durban

6001

Port Elizabeth

6009

Nedlands

7925

Cape Town

15243

Pittsburgh

19001

Abington

19107

Philadelphia

19114

Philadelphia

19446

Lansdale

23233

Richmond

23294

Richmond

23456

Virginia Beach

23507

Norfolk

27103

Winston-Salem

27612

Raleigh

27710

Durham

28562

New Bern

29201

Columbia

29607

Greenville

30066

Marietta

33324

Plantation

33401

West Palm Beach

33409

West Palm Beach

33759

Clearwater

34285

Venice

34652

New Port Richey

36116

Montgomery

37403

Chattanooga

37620

Bristol

38119

Memphis

44122

Cleveland

45342

Miamisburg

47714

Evansville

53792

Madison

60523

Oak Brook

73112

Oklahoma City

78229

San Antonio

78414

Corpus Christi

80202

Denver

80206

Denver

83404

Idaho Falls

84120

West Valley City

85032

Phoenix

85035

Phoenix

85225

Chandler

85712

Tucson

89502

Reno

92083

Vista

94115

San Francisco

97210

Portland

98055

Renton

06050

New Britain

08648

Lawrenceville

T2N 4L7

Calgary

V6Z 1Y6

Vancouver

R3A 1R9

Winnipeg

B3H 2N1

Halifax

N6A 4V2

London

M5B 1W8

Toronto

S7K 1N4

Saskatoon

Unknown

Hong Kong

NG7 2UH

Nottingham

G51 4TF

Glasgow

S10 2SF

Sheffield

SN3 6BD

Swindon

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00318500 - Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women | Biotech Hunter | Biotech Hunter